首页> 外文期刊>Practical diabetes international : >Limitations of glycosylated haemoglobin (HbA1c) in diabetes screening
【24h】

Limitations of glycosylated haemoglobin (HbA1c) in diabetes screening

机译:糖化血红蛋白(HbA1c)在糖尿病筛查中的局限性

获取原文
获取原文并翻译 | 示例
           

摘要

Recently, glycosylated haemoglobin (HbA1c) has been recommended by the American Diabetes Association (ADA), the World Health Organisation and subsequently by many other professional bodies as a diagnostic tool for diabetes mellitus. However, the cut-off values suggested vary between these groups and uncertainties remain regarding the limitations of this test and its effectiveness as a diagnostic tool. We wished to assess the effect of HbA1c on detection rates for dysglycaemia in a high risk cohort of 200 patients with possible acute coronary syndrome not previously known to have diabetes. Anthropometric as well as HbA1c, oral glucose tolerance tests (OGTT), random and fasting plasma glucose (RPG and FPG) concentrations, fasting lipids and high sensitivity C-reactive protein data were obtained during admission. We examined each of the recommended cut-off values for HbA1c, Test accuracy was assessed by the degree of misdassification (both under- and over-diagnosis) of patients into normal glycaemic control, impaired glucose tolerance and diabetes mellitus based on OGTT data using WHO criteria. A predictive index (PI) was generated using stepwise ordinal regression models (incorporating FPG, HbA1c, HDL-C, triglycerides, age and gender). HbA1c alone, using the International Expert Committee cut-off values, had unacceptably high misclassification rates (49.0% under- and 2.5% over-diagnosed).This did not improve when ADA criteria were examined, despite their lower cut-off values for normoglycaemia (44.4% under- and 7.1% over-diagnosed). FPG was marginally better, misclassifying 44.4% (mostly under-diagnosis; 41.4%). The PI had the lowest misclassification rate (35.9%; with 22.7% under- and 13.1 % over-diagnosed). In conclusion, our data suggest that HbA1c alone offers little advantage over FPG in detecting dysglycaemia in this high risk population. Our approach using a predictive index to combine HbA1c with other test data will enhance its performance.
机译:最近,糖化血红蛋白(HbA1c)已被美国糖尿病协会(ADA),世界卫生组织以及随后的许多其他专业机构推荐作为糖尿病的诊断工具。但是,建议的临界值在这些组之间有所不同,关于该测试的局限性及其作为诊断工具的有效性仍存在不确定性。我们希望评估HbA1c对200例先前未曾患有糖尿病的可能患有急性冠脉综合征的高危人群中血糖检测率的影响。入院期间获得人体测量学和HbA1c,口服葡萄糖耐量测试(OGTT),随机和空腹血浆葡萄糖(RPG和FPG)浓度,空腹血脂和高敏感性C反应蛋白数据。我们检查了每个推荐的HbA1c临界值,通过使用WHO的OGTT数据,通过对患者进行正常血糖控制,糖耐量降低和糖尿病的误入歧义程度(诊断不足和过度诊断)来评估测试准确性标准。使用逐步序数回归模型(结合FPG,HbA1c,HDL-C,甘油三酸酯,年龄和性别)生成预测指数(PI)。仅使用国际专家委员会的临界值的HbA1c误分类率就高得令人难以接受(误诊率分别为49.0%和2.5%以上),尽管按照ADA标准进行检查,尽管正常血糖的临界值较低,但这种情况并没有改善(低于诊断水平的44.4%和高于诊断水平的7.1%)。 FPG稍好一些,错误分类为44.4%(大多数为诊断不足; 41.4%)。 PI的误分类率最低(35.9%;诊断不足和误诊率分别为22.7%和13.1%)。总之,我们的数据表明,在检测这种高危人群的血糖异常中,单独使用HbA1c不能提供优于FPG的优势。我们使用预测指标将HbA1c与其他测试数据结合的方法将增强其性能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号